In vivo capture and label-free detection of early metastatic cells.
In vivo capture and label-free detection of early metastatic cells.
复制标题
DOI：
10.1038/ncomms9094
复制
发表时间：
2015-09-08
影响因子：
16.6
通讯作者：
Shea LD
中科院分区：
文献类型：
--
作者：
Azarin SM;Yi J;Gower RM;Aguado BA;Sullivan ME;Goodman AG;Jiang EJ;Rao SS;Ren Y;Tucker SL;Backman V;Jeruss JS;Shea LD
乳腺癌是女性死亡的主要原因，转移是导致死亡的原因。一旦肿瘤细胞影响到实体器官的功能，通常就会发现转移，高的疾病负担限制了有效的治疗。在这里，我们报道了一种通过植入支架在体内招募和捕获转移细胞来早期检测转移的方法，该方法实现了高细胞密度，并将实体器官内的肿瘤负担减少了10倍。募集与免疫细胞的渗透有关，其中包括Gr1hiCD11b+细胞。我们通过使用反向光谱光学相干断层扫描的无标记检测系统来识别支架中的转移细胞，该系统识别与肿瘤细胞的存在相关的纳米级组织结构的变化。对于有复发风险的患者，在完成初步治疗后植入支架有可能在最早阶段发现转移疾病，使患者能够在疾病负担较低的情况下开始治疗。
Breast cancer is a leading cause of death for women, with mortality resulting from metastasis. Metastases are often detected once tumor cells affect the function of solid organs, with a high disease burden limiting effective treatment. Here we report a method for the early detection of metastasis using an implanted scaffold to recruit and capture metastatic cells in vivo, which achieves high cell densities and reduces the tumor burden within solid organs 10-fold. Recruitment is associated with infiltration of immune cells, which include Gr1hiCD11b+ cells. We identify metastatic cells in the scaffold through a label-free detection system using inverse-spectroscopic optical coherence tomography, which identifies changes to nanoscale tissue architecture associated with the presence of tumor cells. For patients at risk of recurrence, scaffold implantation following completion of primary therapy has the potential to identify metastatic disease at the earliest stage, enabling initiation of therapy while the disease burden is low.